Key takeaways
- Novo Nordisk has launched the OASIS-5 clinical trial to evaluate lower daily maintenance doses for its oral Wegovy pill.
- The 60-week study will follow 450 overweight or obese adults without diabetes to find the lowest dose that maintains weight loss.
- If successful, smaller maintenance doses could help patients minimize gastrointestinal side effects and lower out-of-pocket costs.
- This trial represents a clinical shift toward validating "microdosing" strategies that many GLP-1 patients already practice independently.
What happened
On August 12, 2026, Danish drugmaker Novo Nordisk officially launched OASIS-5, a new 60-week Phase 3 clinical trial designed to evaluate lower daily maintenance doses of its oral Wegovy (semaglutide) pill. According to clinical trial registry details reported by Reuters on August 19, 2026, the study aims to establish the lowest effective dose of the daily weight-loss medication that can successfully prevent weight regain while improving tolerability for patients.
Why it matters
This trial marks a major strategic shift in how pharmaceutical companies approach obesity drug maintenance. Currently, the FDA-approved long-term maintenance dose for the oral Wegovy pill is 25 milligrams, which must be taken daily. However, many patients struggle with severe gastrointestinal side effects at these maximum therapeutic strengths, leading to high discontinuation rates.
For cash-paying consumers in the United States, finding a lower effective maintenance dose is highly significant. If Novo Nordisk establishes that a much smaller daily pill can successfully maintain weight loss, it could provide a formalized path for "microdosing." This practice allows patients to manage their chronic metabolic health with fewer side effects and potentially reduces the massive out-of-pocket costs associated with purchasing maximum-dose brand-name medications every month.
What the data says
The OASIS-5 trial is a rigorous, late-stage study slated to run until 2028. Based on details retrieved from the U.S. clinical trials database and reported by Reuters, here are the key parameters of the study:
- Participants: The trial will enroll 450 adult participants who do not have diabetes.
- Eligibility Criteria: Participants must have a Body Mass Index (BMI) of 30 or higher, or a BMI of 27 or higher alongside at least one weight-related health condition.
- Exclusions: Anyone with a history of diabetes, recent major weight fluctuations, or current treatment using GLP-1 receptor agonists will be excluded.
- Duration: The study is structured to last 60 weeks.
- Primary Objective: Researchers will measure whether lower maintenance doses of oral semaglutide result in superior weight loss and weight maintenance compared to a placebo.
- Secondary Objectives: The trial will track alterations in waist circumference, overall side effect profiles, and broader metabolic health benefits.
While Novo Nordisk has not yet specified the exact milligram strengths of the new experimental low doses, the oral Wegovy pill is already approved in step-up doses of 1.5 mg, 4 mg, and 9 mg, before reaching the 25 mg maintenance ceiling.
How it compares
The push for a lower-dose oral option comes as Novo Nordisk faces fierce competition from Eli Lilly. In the second quarter of 2026 alone, Novo Nordisk's oral Wegovy pill brought in 3.22 billion Danish crowns (approximately $499.89 million USD), highlighting the massive consumer appetite for needle-free alternatives.
For patients shopping for weight-loss solutions, daily pills offer a distinct lifestyle advantage over weekly subcutaneous injections. However, oral semaglutide has historically suffered from very low bioavailability—meaning the body only absorbs a tiny fraction of the active drug through the stomach lining, requiring much higher raw milligram doses (up to 25 mg daily) compared to weekly injections (which max out at 2.4 mg per week).
In contrast, Eli Lilly’s experimental oral GLP-1 drug, Orforglipron (marketed under the name Foundayo), is being evaluated at much lower approved target doses, such as 0.8 mg and 2.5 mg. If Novo Nordisk can validate smaller maintenance doses for its oral pill, it will close the gap on tolerability and dose efficiency against Lilly's pipeline.
For US buyers, this comparison is also financial. Patients paying out-of-pocket for brand-name GLP-1 therapies often face retail prices exceeding $1,000 per month. By validating lower maintenance doses, physicians may gain the clinical confidence to write prescriptions for lower, less expensive strengths, or space out doses, helping consumers stretch their healthcare dollars.
How this fits the bigger picture
The launch of the OASIS-5 trial is a direct response to a grassroots trend: patient-led microdosing. As Novo Nordisk International Operations President Mike Doustdar acknowledged to Reuters, many patients already take lower-than-approved doses of GLP-1 drugs on their own to manage side effects and stretch their supplies.
This study closely connects to previous clinical milestones. For instance, our prior coverage on how a trial shows switching to oral GLP-1 maintains weight loss highlighted the growing role of oral medications as long-term maintenance tools after patients lose initial weight on injectable therapies. Similarly, when the FDA approved the oral Wegovy pill, it opened a vital needle-free path for telehealth buyers, though high costs and gastrointestinal issues remained persistent barriers.
By scientifically validating "microdoses," Novo Nordisk is attempting to institutionalize a practice that patients have used to bypass the side effects that plague the class. For consumers navigating telehealth marketplaces to find the cheapest telehealth GLP-1 options, clinical validation of lower maintenance doses could eventually reshape standard commercial prescribing guidelines, making long-term weight maintenance both physically and financially sustainable.
What happens next
The OASIS-5 trial is currently recruiting participants, with clinical monitoring and data collection scheduled to continue through 2028. In the meantime, Novo Nordisk will continue to manufacture and distribute its current approved strengths of the oral Wegovy pill (1.5 mg to 25 mg).
Consumers looking for lower-dose options or affordable maintenance strategies can consult with licensed healthcare providers to explore off-label dosing protocols or compare alternative, customizable formulations. To view current pricing, clinical requirements, and compounding options across major US digital health platforms, you can explore our comprehensive interactive provider comparison tool.
Disclaimer: CompareRx does not provide medical advice. Always consult a qualified healthcare professional before starting, stopping, or altering the dosage of any medication.